Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has been assigned a $3.00 price objective by Maxim Group in a report released on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target would indicate a potential upside of 328.57% from the stock’s previous close.

The analysts wrote, “Actinium presented a poster: A Phase 2 Study of Actinium-225 (225Ac)- Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy”.””

Other equities analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Roth Capital reiterated a “buy” rating and set a $6.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd.

Actinium Pharmaceuticals (ATNM) remained flat at $$0.70 on Wednesday. 738,000 shares of the company traded hands, compared to its average volume of 713,148. Actinium Pharmaceuticals has a 1-year low of $0.54 and a 1-year high of $1.72.

ILLEGAL ACTIVITY NOTICE: “Actinium Pharmaceuticals (ATNM) PT Set at $3.00 by Maxim Group” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/06/actinium-pharmaceuticals-atnm-pt-set-at-3-00-by-maxim-group.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.